These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7930752)

  • 1. Successes and failures in measles control.
    Cutts FT; Markowitz LE
    J Infect Dis; 1994 Nov; 170 Suppl 1():S32-41. PubMed ID: 7930752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Viruses in the Therapy of Lymphoproliferative Diseases.
    Vorobyev PO; Babaeva FE; Panova AV; Shakiba J; Kravchenko SK; Soboleva AV; Lipatova AV
    Mol Biol; 2022; 56(5):684-695. PubMed ID: 36217339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Content Uniformity in MMR Vaccine.
    Isaacs JT; Almeter PJ; Henderson BS; Hunter AN; Platt TL; Lodder RA
    Contact Context; 2022; 2022():. PubMed ID: 35360461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the nationwide transmission risk of measles in US schools and impacts of vaccination and supplemental infection control strategies.
    Azimi P; Keshavarz Z; Cedeno Laurent JG; Allen JG
    BMC Infect Dis; 2020 Jul; 20(1):497. PubMed ID: 32652940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam?
    Li Y; Shen Y; Zhao R; Samudio I; Jia W; Bai X; Liang T
    Cancer Med; 2020 May; 9(9):2943-2959. PubMed ID: 32130786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of measles viruses in China: Circulation dynamics of the endemic H1 genotype from 2011 to 2017.
    Wang H; Zhang Y; Mao N; Zhu Z; Cui A; Xu S; Song J; Chen M; Fang X; Li C; Feng D; Zhou S; Wang S; Shi J; Ji Y; Cao L; Ren L; Gao L; Xu W
    PLoS One; 2019; 14(6):e0218782. PubMed ID: 31220172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measles Epidemics in Romania: Lessons for Public Health and Future Policy.
    Dascalu S
    Front Public Health; 2019; 7():98. PubMed ID: 31073518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seasonal gaps in measles vaccination coverage in Madagascar.
    Mensah K; Heraud JM; Takahashi S; Winter AK; Metcalf CJE; Wesolowski A
    Vaccine; 2019 Apr; 37(18):2511-2519. PubMed ID: 30940486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Bioinformatics Analysis of the Immune Mechanism of Dendritic Cells Against Measles Virus.
    Jia L; Zhang R
    Med Sci Monit; 2019 Feb; 25():903-912. PubMed ID: 30705250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 'post-honeymoon' measles epidemic in Burundi: mathematical model-based analysis and implications for vaccination timing.
    Corey KC; Noymer A
    PeerJ; 2016; 4():e2476. PubMed ID: 27672515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
    Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
    Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma.
    Domingo-Musibay E; Allen C; Kurokawa C; Hardcastle JJ; Aderca I; Msaouel P; Bansal A; Jiang H; DeGrado TR; Galanis E
    Cancer Gene Ther; 2014 Nov; 21(11):483-90. PubMed ID: 25394505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials.
    Hartkopf AD; Fehm T; Wallwiener M; Lauer U
    Geburtshilfe Frauenheilkd; 2012 Feb; 72(2):132-136. PubMed ID: 25374430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 60-year review on the changing epidemiology of measles in capital Beijing, China, 1951-2011.
    Li J; Lu L; Pang X; Sun M; Ma R; Liu D; Wu J
    BMC Public Health; 2013 Oct; 13():986. PubMed ID: 24143899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying high-risk areas for sporadic measles outbreaks: lessons from South Africa.
    Sartorius B; Cohen C; Chirwa T; Ntshoe G; Puren A; Hofman K
    Bull World Health Organ; 2013 Mar; 91(3):174-83. PubMed ID: 23476090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research priorities for global measles and rubella control and eradication.
    Goodson JL; Chu SY; Rota PA; Moss WJ; Featherstone DA; Vijayaraghavan M; Thompson KM; Martin R; Reef S; Strebel PM
    Vaccine; 2012 Jul; 30(32):4709-16. PubMed ID: 22549089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of medulloblastoma with a modified measles virus.
    Studebaker AW; Kreofsky CR; Pierson CR; Russell SJ; Galanis E; Raffel C
    Neuro Oncol; 2010 Oct; 12(10):1034-42. PubMed ID: 20494960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
    Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
    Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
    Msaouel P; Dispenzieri A; Galanis E
    Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.